GSK downgraded on Avandia withdrawal fears; Big Pharma's likely bidders for Savient;

 @FiercePharma: FDA panel nixes restrictions on cough meds. Report | Follow @FiercePharma

> GlaxoSmithKline was downgraded by the Jeffries investment firm, which predicts that its diabetes drug Avandia will be pulled off the European market. Report

> With Savient Pharmaceuticals and its new gout drug on the block, analysts peg Johnson & Johnson, Abbott Laboratories, Pfizer and Amgen as possible bidders. Report

> Kidney patients who respond poorly to anemia drugs such as Amgen's Aranesp experience a significantly increased risk of heart problems and death. Report

> AstraZeneca has nabbed another generics supplier in India: Intas Pharmaceuticals, which has agreed to a licensing and supply deal covering off-patent cancer drugs made in Matoda, India. Report

> Australia's Sigma Pharmaceuticals said it will slash between A$220 million and A$270 million ($206 million-$253 million) off the value of its drug manufacturing arm in its upcoming results. Report

> Fears that acne drugs like Roche's Accutane could cause depression may have been overblown, since the condition itself is strongly linked to suicidal thoughts and depression, scientists say. Report

> Generic drugmaker Perrigo will take applications and resumes for 70 jobs for its Allegan and Holland plants next week at the Michigan Works Office in Holland, Michigan. Report

> Lundbeck is confident that the launch of its big-selling antidepressant Cipralex (escitalopram) in Japan in the near future will make a major contribution to its coffers. Report

Biotech News

@FierceBiotech: FierceBiotech's 2010 Fierce 15. Report | Follow @FierceBiotech

@JohnCFierce: Millennium CEO Deb Dunsire on diagnostics and drugs: "We're not there yet." Not that many single gene disease drivers. | @JohnCFierce

> Arena faces FDA panel today. News

> Burrill gets "firm commitment" for $1B to back biotech park. Article

> Bluebird in spotlight after gene therapy cures blood disorder. Story

Vaccines News

> Novartis' meningitis B vax passes test. Item

> New study shows no link between vaccines, autism. Report

> Inovio reports clinical success for cervical cancer vax. News

> NanoBio unveils promising data on next-gen vaccine. Article

Manufacturing News

> Despite disposables, steel tank maker expands. Article

> FDA defines "fix zone" for BMS aseptic fill violations. Report

> Planned hires take sting out of Genzyme layoffs. News

> Officials nab high tech, low tech counterfeiters. Story

> KV ops momentum grows with $20M loan. Item

And Finally... Eli Lilly has jumped feet first into the social media scene this week, launching a corporate blog and a Twitter account. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.